{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-199430","form_type":"8-K","ticker":"MREO","cik":"0001719714","company_name":"Mereo BioPharma Group plc","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.254580+00:00","generated_at":"2026-05-31T09:45:32.045384+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Mereo BioPharma Q2 net loss $12.3M; setrusumab studies fully enrolled, fracture rate cut 67%","bullets":["Cash $87.4M as of June 30, 2024, including $50M June offering; runway into 2027.","Net loss $12.3M in Q2 2024 vs $1.8M in Q2 2023, driven by $9.0M milestone payment in prior year.","Phase 3 Orbit and Cosmic studies of setrusumab in OI fully enrolled by April 30, 2024.","Setrusumab reduced median annualized fracture rate by 67% (p=0.0014) over 16 months mean treatment.","R&D expenses $4.9M (+33% YoY); G&A expenses $7.9M (+$5.2M) on pre-commercial activity."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-199430","json":"https://secwatch.observer/filing/0001193125-24-199430.json","markdown":"https://secwatch.observer/filing/0001193125-24-199430.md","text":"https://secwatch.observer/filing/0001193125-24-199430.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719714/000119312524199430/0001193125-24-199430-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719714/000119312524199430/d880557d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:45:32.045384+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}